Acer Therapeutics Inc
ACER
ACER was delisted on the 8th of November, 2023.
30 hedge funds and large institutions have $6.67M invested in Acer Therapeutics Inc in 2020 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
20% more capital invested
Capital invested by funds: $5.53M → $6.67M (+$1.13M)
11% more funds holding
Funds holding: 27 → 30 (+3)
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $13K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$969K |
| 2 |
Goldman Sachs
New York
|
+$154K |
| 3 |
HAG
HighPoint Advisor Group
Downers Grove,
Illinois
|
+$78.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$44.4K |
| 5 |
Two Sigma Investments
New York
|
+$34.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$237K |
| 2 |
State Street
Boston,
Massachusetts
|
-$37K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$21.3K |
| 4 |
Two Sigma Advisers
New York
|
-$11.3K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$10K |
ACER Hedge Fund Activity: Q4 2020 in Review
30 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Acer Therapeutics Inc (ACER) for Q4 2020, worth a combined $6.67M — up 20% from $5.53M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ACER positions and 5 closed out — a net gain of 3 holders — while 2 added to existing stakes and 8 trimmed.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $969K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $237K sold.
- 30 institutional investors held Acer Therapeutics Inc (ACER) as of Q4 2020, up from 27 in Q3 2020.
- Funds reported $6.67M of Acer Therapeutics Inc stock for Q4 2020, up 20% quarter-over-quarter.
- 8 funds opened new Acer Therapeutics Inc positions in Q4 2020 and 5 closed out, a net change of +3 holders.
- The largest Acer Therapeutics Inc buyer in Q4 2020 was J. Goldman & Co, an estimated $969K added.
- The largest Acer Therapeutics Inc seller in Q4 2020 was GSA Capital Partners, an estimated $237K sold.
Based on aggregated 13F filings for Q4 2020.